Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 11Neoplasms 4Adenocarcinoma of Lung 4Brain Neoplasms 3Adenocarcinoma, Bronchiolo-Alveolar 3Neoplasm Metastasis 2NSCLC 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Diseases 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Head and Neck Neoplasms 1EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors 1Carcinoma 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 1aumolertinib 1anlotinib 1abivertinib 1Radiosurgery 1Pemetrexed 1Gefitinib 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Non-small Cell Lung Cancer × Gefitinib × Clear all
NCT03856697 2019-02-27

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Phase 3 Unknown
406 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡